Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 111 participants.

Also called NCT04416048

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 111 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04416048
  • EudraCT 2020-002282-33
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT04416048. Randomized; no masking; primary purpose prevention. Start 2020-11-30 (actual); primary completion 2021-07-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19
Acronym
COVID-PREVENT
Condition
COVID-19
Intervention (Drug)
Rivaroxaban
Intervention (Other)
Standard Of Care (SOC)
Lead sponsor
Charite University, Berlin, Germany (class: other)
Collaborator
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) (class: other)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct04416048
Content hash
28dd16fa86473b420ef2c6ef2644ecde448de484e777aa842044091bb9fc53ea